Several new treatment options for patients with breast cancer have emerged over the last few years, including more oral ...
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/2.DN-d7ZPu.js ...
Enhertu is a HER2-directed antibody and topoisomerase inhibitor conjugate. Approval of the new indication was based on data from the phase 3 DESTINY-Breast06 trial (ClinicalTrials.gov Identifier: ...
SAN MATEO, Calif. - Vincerx Pharma, Inc. (NASDAQ:VINC), a clinical-stage biopharmaceutical company with a current market capitalization of $2.77 million, and Oqory, Inc. announced promising results ...
Companies also provide insights into proposed strategic mergerSAN MATEO, Calif., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Vincerx ...
Tate High School volleyball has been honored with the 2024-2025 Sideout Foundation Philanthropic Achievement Award.
Asymptomatic brain metastasis in stage 4 breast cancer requires reevaluation of screening guidelines
A new study led by researchers at Moffitt Cancer Center shows that asymptomatic brain metastasis is more common in stage 4 breast cancer patients than previously believed.
The Phase III trial saw a clinically meaningful benefit in overall survival with a combination of Itovebi alongside Ibrance ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback